Showing results (71-80 of 242) with videos related to
Sort By:
Pageof 25
Lancet (London, England)|September 7, 2016
New and emerging targeted treatments in advanced non-small-cell lung cancerFred R Hirsch, Kenichi Suda, Jacinta Wiens, et al.Advances in Therapy|June 25, 2024
Real-World Treatment Patterns and Outcomes Across Three Lines of Therapy in Patients with ALK+ NSCLCKonstantinos Arnaoutakis, Yin Wan, Jennifer Elliott, et al.Journal of Bioinformatics and Systems Biology : Open Access|May 22, 2024
Linear Regression of Sampling Distributions of the MeanDavid J Torres, Ana Vasilic, Jose PachecoClinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 22, 2006
Selecting lung cancer patients for treatment with epidermal growth factor receptor tyrosine kinase inhibitors by immunohistochemistry and fluorescence in situ hybridization--why, when, and how?Rafal Dziadziuszko, Fred R Hirsch, Marileila Varella-Garcia, et al.Platelets|October 30, 2014
Dipstick proteinuria is an independent predictor of high on treatment platelet reactivity in patients on clopidogrel, but not aspirin, admitted for major adverse cardiovascular eventsCarlos D Davila, Fernando Vargas, Kuan-Hsiang Gary Huang, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 8, 2010
The tissue is the issue: personalized medicine for non-small cell lung cancerFred R Hirsch, Murry W Wynes, David R Gandara, et al.Seminars in Oncology|March 15, 2002
ZD1839, a selective epidermal growth factor receptor tyrosine kinase inhibitor, alone and in combination with radiation and chemotherapy as a new therapeutic strategy in non-small cell lung cancerDavid Raben, Barbara A Helfrich, Dan Chan, et al.Medical Oncology (Northwood, London, England)|July 17, 2017
Local and systemic immunity predict survival in patients with pulmonary sarcomatoid carcinomaErin Schenk, Jennifer Boland, Aaron Mansfield, et al.Frontiers in Oncology|April 16, 2019
A Changing of the Guard: Immune Checkpoint Inhibitors With and Without Chemotherapy as First Line Treatment for Metastatic Non-small Cell Lung CancerJose M Pacheco, D Ross Camidge, Robert C Doebele, et al.Clinical Lung Cancer|June 15, 2007
Single-institution experience with pemetrexed and bevacizumab as salvage therapy in advanced non-small-cell lung cancerGlen J Weiss, Chan Zeng, Karen Kelly, et al.Pageof 25